Broken promise doctrine in Canada poses questions for courts
13 July 2017
|
Natalie Rahhal, New York
The rejection of the promise doctrine has brought Canada into line with other countries and been welcomed by pharmaceutical companies. It also raises questions such as how courts will determine the “subject matter of the invention” and how the enhanced disclosure requirement will be resolved
The so-called “promise doctrine” has been the most talked-about issue in Canadian patent law for the past several years. Patent holders, attorneys and inventors have eagerly waited for the Supreme Court of Canada to decide whether or not the doctrine...
Please
log in to read the rest of this article.
New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Already registered?
Please make sure you log in to read the rest of the article.
Log in
Join us now
Gain FREE access to up to five free articles when you register now. Join here